Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)–associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients

Joseph R. Stoll; Laura Battle; Andrea Moy; Stephen W. Dusza; Jae H. Park; Martin S. Tallman; Justin Taylor; Alina Markova

doi:10.1016/j.jaad.2021.01.096

Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)–associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients

Joseph R. Stoll, Laura Battle, Andrea Moy, Stephen W. Dusza, Jae H. Park, Martin S. Tallman, Justin Taylor, Alina Markova^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Original language	English (US)
Pages (from-to)	232-234
Number of pages	3
Journal	Journal of the American Academy of Dermatology
Volume	86
Issue number	1
DOIs	https://doi.org/10.1016/j.jaad.2021.01.096
State	Published - Jan 2022

Funding

Funding sources: Dr Markova was supported by a Dermatology Foundation Career Development Award. This study was also funded in part by a grant from the National Cancer Institute/National Institutes of Health (P30-CA008748) made to the Memorial Sloan Kettering Cancer Center.Dr Park has served on the advisory board of Artiva and has served as a consultant for Amgen, Novartis, Kite Pharma, Intellia, Allogene, Incyte, Takeda, Servier, AstraZeneca, and Autolus. Dr Tallman has served on the advisory board of AbbVie, BioLineRx, Daiichi-Sankyo, Orsenix, KAHR, Rigel, Nohla, Delta Fly Pharma, Tetraphase, Oncolyze, Jazz Pharma, Roche, Biosight; has received research funding from AbbVie, Cellerant, Orsenix, ADC Therapeutics, Biosight, and Glycomimetics, and receives royalties from UpToDate. Dr Markova has served on the advisory board of AstraZeneca and has received research funding from Incyte. Author Stoll and Drs Battle, Moy, Dusza, and Taylor have no conflicts of interest to declare.

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jaad.2021.01.096

Cite this

Stoll, J. R., Battle, L., Moy, A., Dusza, S. W., Park, J. H., Tallman, M. S., Taylor, J., & Markova, A. (2022). Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)–associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients. Journal of the American Academy of Dermatology, 86(1), 232-234. https://doi.org/10.1016/j.jaad.2021.01.096

@article{c895054474384d6c9513a78ea674dd5d,

title = "Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)–associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients",

author = "Stoll, {Joseph R.} and Laura Battle and Andrea Moy and Dusza, {Stephen W.} and Park, {Jae H.} and Tallman, {Martin S.} and Justin Taylor and Alina Markova",

note = "Funding Information: Funding sources: Dr Markova was supported by a Dermatology Foundation Career Development Award. This study was also funded in part by a grant from the National Cancer Institute/National Institutes of Health (P30-CA008748) made to the Memorial Sloan Kettering Cancer Center.Dr Park has served on the advisory board of Artiva and has served as a consultant for Amgen, Novartis, Kite Pharma, Intellia, Allogene, Incyte, Takeda, Servier, AstraZeneca, and Autolus. Dr Tallman has served on the advisory board of AbbVie, BioLineRx, Daiichi-Sankyo, Orsenix, KAHR, Rigel, Nohla, Delta Fly Pharma, Tetraphase, Oncolyze, Jazz Pharma, Roche, Biosight; has received research funding from AbbVie, Cellerant, Orsenix, ADC Therapeutics, Biosight, and Glycomimetics, and receives royalties from UpToDate. Dr Markova has served on the advisory board of AstraZeneca and has received research funding from Incyte. Author Stoll and Drs Battle, Moy, Dusza, and Taylor have no conflicts of interest to declare.",

year = "2022",

month = jan,

doi = "10.1016/j.jaad.2021.01.096",

language = "English (US)",

volume = "86",

pages = "232--234",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Elsevier Inc.",

number = "1",

}

Stoll, JR, Battle, L, Moy, A, Dusza, SW, Park, JH, Tallman, MS, Taylor, J & Markova, A 2022, 'Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)–associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients', Journal of the American Academy of Dermatology, vol. 86, no. 1, pp. 232-234. https://doi.org/10.1016/j.jaad.2021.01.096

Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)–associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients. / Stoll, Joseph R.; Battle, Laura; Moy, Andrea et al.
In: Journal of the American Academy of Dermatology, Vol. 86, No. 1, 01.2022, p. 232-234.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)–associated distinct purpuric subtype of toxic erythema of chemotherapy

T2 - A retrospective review of 54 patients

AU - Stoll, Joseph R.

AU - Battle, Laura

AU - Moy, Andrea

AU - Dusza, Stephen W.

AU - Park, Jae H.

AU - Tallman, Martin S.

AU - Taylor, Justin

AU - Markova, Alina

N1 - Funding Information: Funding sources: Dr Markova was supported by a Dermatology Foundation Career Development Award. This study was also funded in part by a grant from the National Cancer Institute/National Institutes of Health (P30-CA008748) made to the Memorial Sloan Kettering Cancer Center.Dr Park has served on the advisory board of Artiva and has served as a consultant for Amgen, Novartis, Kite Pharma, Intellia, Allogene, Incyte, Takeda, Servier, AstraZeneca, and Autolus. Dr Tallman has served on the advisory board of AbbVie, BioLineRx, Daiichi-Sankyo, Orsenix, KAHR, Rigel, Nohla, Delta Fly Pharma, Tetraphase, Oncolyze, Jazz Pharma, Roche, Biosight; has received research funding from AbbVie, Cellerant, Orsenix, ADC Therapeutics, Biosight, and Glycomimetics, and receives royalties from UpToDate. Dr Markova has served on the advisory board of AstraZeneca and has received research funding from Incyte. Author Stoll and Drs Battle, Moy, Dusza, and Taylor have no conflicts of interest to declare.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85102742018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85102742018&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2021.01.096

DO - 10.1016/j.jaad.2021.01.096

M3 - Article

C2 - 33539850

AN - SCOPUS:85102742018

SN - 0190-9622

VL - 86

SP - 232

EP - 234

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 1

ER -

Liposomal cytarabine and daunorubicin (CPX-351/Vyxeos)–associated distinct purpuric subtype of toxic erythema of chemotherapy: A retrospective review of 54 patients

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this